Interview With Chris Kilham, Medicine Hunter Inc.

Digital Therapeutics and Psychedelic Medicines || MindMed’s SECRET WEAPON?!? MindMed (MMED / MMEDF / MMQ) and Atai’s secret weapon lies in the digitalization of psychedelic medicines. MindMed has Albert, their Digital Medicines division, and Atai has their Brain Computer Interface.

Instead of doing our usual “This Week In Psychedelic Stocks episode”, I decided to discuss the article entitled “Digital Therapeutics: Optimizing Psychedelics Therapies With Next-Generation IP” as it pertains to MindMed and Atai and because there wasn’t a lot of interesting news for our usual Psychedelic segment.

Why should investors in psychedelic stocks be deeply interested in these technological advancements? According to Jeff Nielson, there’s two reasons.

1.Generally, next-generation digital technology (which includes the introduction of AI) is already pioneering a tech revolution in healthcare.
2.Specifically, psychedelics-based therapies are one of the areas of medical treatment that will benefit the most from this technology.

I hope you guys found some value in this and I’ll keep you posted for more changes!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

If you wish to collaborate, send us an email at:
thepsychedelicinvestor@gmail.com

Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor

Music: www.bensound.com

Time Stamps:

0:00 – Intro
10:08 – Implications for MindMed and Atai

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed​​ ​#MindmedStock​​ #MMEDNews

Today we are going to be talking about MindMed’s, (MNDM : NASDAQ), (MMED : NEO) patent application made in collaboration with BioXcel Therapeutics.
BioXcel is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology.
The Patent is “for detecting and preventing the early onset of agitation in patients predisposed to highly agitated behaviour”.

Enjoy the episode!

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#mindmed #mmed #mnmdstock

THE MINDMED VS. ATAI discussion you need to hear!

Prior to atai’s IPO on the NASDAQ stock exchange, we repeatedly said that when atai Life Sciences goes public, the company will become MindMed ‘s ( MNMD: NASDAQ) (MMED: NEO) top competitor.

Well, atai did IPO on June 18 under ticker symbol “atai”. For this reason, I invited Jason Najum from Microdose.buzz to have a conversation. In this episode, we have a general discussion about:

– MindMed’s flagship programs and the different businesses and programs ran under atai’s umbrella.
– The companies’ financial capability to run clinical trials.
-MindMed’s and atai’s potential to disrupt the way we treat mental illness within the next 5 to 10 years.
– Potential return on investment for retail investors.

Time Stamps:
0:00 – Intro
4:11 – What is atai’s mission?
6:24 – What is MindMed’s Mission
8:29 – atai’s clinical trial pipeline
19:45 – MindMed’s clinical trial pipeline
24:25 – How do MindMed and atai differ in business structure?
30:40 – Comparing the financials

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Enjoy the episode!

Check out Jason’s writing at:
https://microdose.buzz/

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Website: https://thepsychedelicinvestor.com/

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #MNMD #Atai